Navigation Links
WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
Date:2/5/2009

SHANGHAI, China, Feb. 5 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced the addition of Stewart Hen and Ning Zhao to the WuXi PharmaTech Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Ge Li, WuXi's Chairman and Chief Executive Officer, commented, ''We welcome the addition of Stewart Hen and Ning Zhao to the board. Each brings invaluable expertise as we work to anticipate and meet our customers' evolving needs for improving R&D productivity.''

Mr. Hen is a managing director at Warburg Pincus LLC, a leading global private equity firm. He focuses on investments in biotechnology and pharmaceuticals, including pharmaceutical outsourcing. Mr. Hen has more than 17 years of experience in the life sciences industry. Prior to Warburg Pincus, he was a consultant at McKinsey & Company serving the pharmaceutical industry. Previously, he worked at Merck in both research and development and manufacturing. Mr. Hen holds an M.B.A. from the Wharton School of the University of Pennsylvania and an M.S. in chemical engineering from the Massachusetts Institute of Technology.

Dr. Zhao, one of WuXi's co-founders, is currently lead advisor to the company's analytical services operations. She was vice president of WuXi's analytical department from 2004 to 2008 and also established its Bio-Analytical Services, Core Analytical Services, and Analytical Development Services departments. She previously worked for Wyeth as a senior research scientist, for Pharmacopeia as a group leader for the high-throughput analysis of combinatorial libraries, and for Bristol-Myers Squibb as a site leader in the Discovery Analytical Sciences department. Dr. Zhao is the co-inventor of numerous patents and has published and presented more than 36 scientific papers. With more than 10 years' experience in analytical sciences in the U.S. pharmaceutical industry, she has received numerous awards, including the 2002 Chemistry Leadership Award from Bristol-Myers Squibb and the 1995 Pegram Award from Columbia University, where she received her Ph.D. Dr. Zhao is married to Dr. Li.

Separately, WuXi announced that Mr. Tao Lin, the company's Vice President of Internal Operations since 2002 and a director of the company since 2005, has resigned from the board of directors and as a company officer for personal reasons. Mr. Lin was one of the founders of the company.

''I want to personally thank Tao for his counsel and wisdom while serving on our board,'' said Dr. Li. ''As a founder and key executive of the company, Tao made many contributions to build WuXi from a start-up to the strong company we are today. We all wish him well.''

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: ir@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
2. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
3. WuXi PharmaTech Announces Second Quarter 2008 Results
4. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
5. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
6. WuXi PharmaTech 2007 Annual Report Available Online
7. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
8. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
9. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
10. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
11. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology: